Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees

Drug Metabolism and Disposition

Volumn 27, Issue 12, 1999, Pages 1434-1447

  Riska, Paul S ^a   Joseph, David P ^a   Dinallo, Roger M ^a   Davidson, Walter C ^a   Keirns, James J ^a   Hattox, Susan E ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CHIMPANZEE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT;

ANIMALS; BILE; BIOTRANSFORMATION; DOGS; FECES; FEMALE; GLUCURONIDASE; HAPLORHINI; HIV-1 REVERSE TRANSCRIPTASE; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MICE; NEVIRAPINE; PAN TROGLODYTES; RABBITS; RATS; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; SPECIES SPECIFICITY;

EID: 0032701771     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kohlstaedt LA, Wang J, Friedman JM, Rice PA and Steitz TA (1992) Crystal structure at 3.5 angstrom resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (Wash DC) 256:1783-1790.
2. Koup RA, Brewster F, Grob P and Sullivan JL (1993) Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon, or CD4 immunoadhesion. AIDS 7:1181-1184.
3. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih C-K, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA and Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (Wash DC) 250:1411-1413.
4. Montaner J, Reiss P, Cooper D, Vella S, Dohnanyi C, Harris M, Conway B, Wainberg M, Smith D, Robinson P, Myers M and Hall D (1998b) Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Feb. 1-5, Chicago, p 695.
5. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M and Lange JM (1998a) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial. JAm Med Assoc 279:930-937.
6. Murphy RL and Montaner J (1996) Nevirapine: A review of it's development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 5:1183-1199.
7. Norris SH, Silverstein HH, St. George RL and Johnstone JN (1992) Nevirapine, an HIV-1 reverse transcriptase inhibitor: Absorption, distribution and excretion in rats. Pharm Res 9:S-263.
8. Riska P, Erickson D, Joseph D, Dinallo R and Hattox S (1996) Nevirapine, a nonnucleoside reverse transcriptase inhibitor: Metabolism in man, mouse, rat, dog, cynomolgus monkey and chimpanzee. XI International Conference on AIDS, July 7-12, Vancouver, British Columbia, Canada.
9. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J and Keirns J (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27: 895-901.
10. Wu JC, Warren TC, Adams J, Proudtoot J, Skiles J, Raghavan P, Perry C, Potocki I, Farina PR and Grob PM (1991) A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubsirate binding site. Biochemistry 30:2022-2026.